Search results
At UCB, we believe that everyone deserves to live the best life that they can. That’s why – as a global biopharmaceutical leader - we’re focused on creating valuable solutions that make improvements to the lives of people living with neurological and autoimmune conditions now and into the future.
- Careers
Let's push the boundaries together and make the most of your...
- Disease Areas
For many years, UCB has responded to changing needs for...
- Our Company
A global biopharma company, inspired by the needs of people...
- UCBCares
UCBCares ® answers questions concerning the treatment with a...
- Investor Relations
At UCB, we aspire to be the patient-preferred biotech...
- Clinical Studies
UCB researchers seek to understand, prevent and treat...
- Newsroom
The UCB media relations team responds to calls and emails...
- Contact
Allée de la Recherche, 60 1070 Brussels Belgium Tel: +32 2...
- Patients
Seizure response dog training is made possible by UCB, Inc....
- Careers
UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.
A global biopharma company, inspired by the needs of people living with severe diseases. At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions.
UCB is a global biopharma company focused on creating value for people living with severe diseases. Learn more about how UCB delivers value for patients through its patient assistance program, treatment tracker and more.
At UCB, we aspire to be the patient-preferred biotech leader. To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general. Our work has an impact on the lives of many people.
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases that have significant unmet needs. By putting people at the heart of everything we do, we enable people to live their best lives, delivering impactful solutions patients value.
People also ask
Who is UCB?
Why should you join UCB?
What does UCB stand for?
Where is UCB located?
When was UCB founded?
What makes UCB the patient-preferred Biotech leader?
Feb 28, 2024 · In 2024, we will accelerate our investments launching three products around the globe, including a direct to consumer (DTC) campaign in the U.S. for BIMZELX®, previously slated for 2023. We are on our way to deliver growth for a decade plus.
